Zhejiang Jingxin Pharmaceutical Co Ltd (002020) - Total Liabilities
Based on the latest financial reports, Zhejiang Jingxin Pharmaceutical Co Ltd (002020) has total liabilities worth CN¥2.29 Billion CNY (≈ $335.56 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Zhejiang Jingxin Pharmaceutical Co Ltd to assess how effectively this company generates cash.
Zhejiang Jingxin Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2024)
This chart illustrates how Zhejiang Jingxin Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Zhejiang Jingxin Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.
Zhejiang Jingxin Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Jingxin Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stock Yards Bancorp Inc
NASDAQ:SYBT
|
USA | $8.52 Billion |
|
Solaria Energía y Medio Ambiente S.A
MC:SLR
|
Spain | €1.60 Billion |
|
Zhejiang Jingu Co Ltd
SHE:002488
|
China | CN¥5.18 Billion |
|
Shenzhen Kingdom SCI Tech Co Ltd
SHG:600446
|
China | CN¥1.54 Billion |
|
Beijing Sojo Electric Co Ltd
SHE:300444
|
China | CN¥6.57 Billion |
|
AUB GROUP LTD.
F:A5H
|
Germany | €2.66 Billion |
|
China Sports Industry Group Co Ltd
SHG:600158
|
China | CN¥2.47 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥2.30 Billion |
Liability Composition Analysis (2001–2024)
This chart breaks down Zhejiang Jingxin Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Zhejiang Jingxin Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Jingxin Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Jingxin Pharmaceutical Co Ltd (2001–2024)
The table below shows the annual total liabilities of Zhejiang Jingxin Pharmaceutical Co Ltd from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.48 Billion ≈ $362.58 Million |
+1.28% |
| 2023-12-31 | CN¥2.45 Billion ≈ $357.99 Million |
+11.68% |
| 2022-12-31 | CN¥2.19 Billion ≈ $320.55 Million |
+38.85% |
| 2021-12-31 | CN¥1.58 Billion ≈ $230.87 Million |
-8.99% |
| 2020-12-31 | CN¥1.73 Billion ≈ $253.68 Million |
-9.44% |
| 2019-12-31 | CN¥1.91 Billion ≈ $280.13 Million |
+34.97% |
| 2018-12-31 | CN¥1.42 Billion ≈ $207.55 Million |
+51.14% |
| 2017-12-31 | CN¥938.43 Million ≈ $137.32 Million |
+8.59% |
| 2016-12-31 | CN¥864.23 Million ≈ $126.46 Million |
+27.21% |
| 2015-12-31 | CN¥679.39 Million ≈ $99.42 Million |
+1.99% |
| 2014-12-31 | CN¥666.12 Million ≈ $97.47 Million |
+31.47% |
| 2013-12-31 | CN¥506.65 Million ≈ $74.14 Million |
-4.12% |
| 2012-12-31 | CN¥528.40 Million ≈ $77.32 Million |
+23.92% |
| 2011-12-31 | CN¥426.39 Million ≈ $62.39 Million |
-32.21% |
| 2010-12-31 | CN¥629.02 Million ≈ $92.05 Million |
+3.11% |
| 2009-12-31 | CN¥610.06 Million ≈ $89.27 Million |
-6.13% |
| 2008-12-31 | CN¥649.89 Million ≈ $95.10 Million |
-9.26% |
| 2007-12-31 | CN¥716.18 Million ≈ $104.80 Million |
+49.76% |
| 2006-12-31 | CN¥478.23 Million ≈ $69.98 Million |
+71.24% |
| 2005-12-31 | CN¥279.27 Million ≈ $40.87 Million |
+54.20% |
| 2004-12-31 | CN¥181.11 Million ≈ $26.50 Million |
+6.31% |
| 2003-12-31 | CN¥170.36 Million ≈ $24.93 Million |
+42.74% |
| 2002-12-31 | CN¥119.35 Million ≈ $17.46 Million |
+6.73% |
| 2001-12-31 | CN¥111.83 Million ≈ $16.36 Million |
-- |
About Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemi… Read more